trending Market Intelligence /marketintelligence/en/news-insights/trending/EVtn42bTM0mWV4SMZSReiw2 content esgSubNav
In This List

Acorda Therapeutics' Parkinson's drug meets safety profile

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Acorda Therapeutics' Parkinson's drug meets safety profile

Acorda Therapeutics Inc. reported results from two safety studies conducted for its Parkinson's drug CVT-301.

The company was studying the safety of its drug in patients with asthma, smokers or those experiencing early-morning "off" periods. Off periods are characterized by the re-emergence of Parkinson's symptoms.

The drug showed consistency in safety profile in both investigations as previously reported in phase 2b and phase 3 clinical trials.

In another study, the patients receiving CVT-301 showed no differences in lung function when compared to those in an observational control group.

Acorda Therapeutics plans to file a new drug application for CVT-301 with the U.S. FDA by the end of the second quarter of 2017.